Active surveillance in low-grade NMIBC — results of an international two-round modified Delphi consensus
- 1 April 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (10) , 691-696
Abstract
Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients. However, the broader adoption of AS is hindered by a lack of standardized protocols for patient selection, monitoring and intervention. To address this gap, we conducted an international, two-round Delphi consensus among 51 bladder cancer experts to establish foundational statements for the use of AS. Consensus was achieved on 20 statements, providing clear recommendations for terminology; inclusion and exclusion criteria; follow-up monitoring; and exit criteria. This Delphi consensus provides the first expert-driven framework to standardize the clinical application of AS for LG-NMIBC. These statements could guide current clinical practice and unify the design of future trials.Keywords
This publication has 18 references indexed in Scilit:
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateEuropean Urology, 2025
- Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)European Urology Oncology, 2024
- Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationEuropean Urology Oncology, 2024
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2024
- When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder CancerEuropean Urology Focus, 2023
- Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non–muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) ExperienceEuropean Urology Oncology, 2022
- Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013JAMA Network Open, 2022
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Watchful Waiting Policy in Recurrent Ta G1 Bladder TumorsEuropean Urology, 2006